Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice.
Antineoplastic Agents
/ therapeutic use
Humans
Imatinib Mesylate
/ therapeutic use
Janus Kinase Inhibitors
/ pharmacology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Myeloproliferative Disorders
/ diagnosis
Primary Myelofibrosis
/ drug therapy
Protein Kinase Inhibitors
/ therapeutic use
Journal
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
ISSN: 1548-8756
Titre abrégé: Am Soc Clin Oncol Educ Book
Pays: United States
ID NLM: 101233985
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
entrez:
6
6
2022
pubmed:
7
6
2022
medline:
9
6
2022
Statut:
ppublish
Résumé
The 1960 discovery of the Philadelphia chromosome in chronic myeloid leukemia (CML) marked the beginning of the modern genomic era of oncology. In the following years, the molecular underpinnings of CML were unraveled, culminating in the development of the first molecularly targeted therapy: imatinib. Imatinib revolutionized CML management, inducing deep molecular responses for most patients and aligning survival curves with those of age-matched control participants. Five additional tyrosine kinase inhibitors are now approved for CML: dasatinib, nilotinib, bosutinib, ponatinib, and asciminib (approved October 2021). The 2005 discovery of
Substances chimiques
Antineoplastic Agents
0
Janus Kinase Inhibitors
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM